Accomplished ITC Lawyer Joins Latham & Watkins in Washington, D.C.

Latham & Watkins appointed Lisa Kattan, who has more than 25 years of ITC and patent litigation experience, as a Washington, D.C. partner and Co-Chair of its ITC Practice. The firm said her arrival adds to a practice that has added five trial lawyers in the past year; Kattan joins from Baker Botts.

Analysis

This is a modest competitive signal in a high-value legal-services niche, not evidence of a change in ITC outcomes or a broad increase in litigation demand. The plausible benefit accrues to Latham & Watkins if the hire helps win mandates spanning Section 337 cases and related district-court, PTAB, appellate, and customs work; that matters because a single dispute can generate work across several forums. The corresponding competitive pressure is on Baker Botts and other firms seeking the same specialist mandates, though one partner move is unlikely to shift the market materially.

For technology and life-sciences companies, deeper specialist capacity may improve access to experienced counsel on both sides of import-related patent disputes. It does not itself alter enforcement risk, exclusion-order exposure, or product economics. The firm's claims about recent trial wins and the hire's potential impact are promotional; independent evidence would require subsequent matter wins, client retention, or practice revenue.

Near term, expect little direct market impact. Over 1–3 months, the useful signal would be whether the hire brings major client mandates or expands Latham's role in active investigations. Over 6–18 months, sustained lateral hiring could strengthen the practice, but could also raise talent-cost and integration risks without corresponding collections. The contrarian point: treating a prominent lateral hire as proof of a rising ITC caseload overreads a firm-level announcement; no public-company exposure or trade catalyst is established here.

Key Decisions for Investors

• No actionable public-equity trade from this announcement alone; Latham and Baker Botts are not mapped public-company securities in the supplied data.
• Track disclosed Section 337 filings, exclusion-order activity, and major client mandates over the next 1–3 months before treating this as a demand signal for litigation services.
• For companies with import-dependent semiconductor, telecom, medical-device, or pharmaceutical products, monitor actual ITC complaints and remedy exposure; a law-firm hire does not change the underlying risk.
• Falsifier for a broader practice-growth thesis: no follow-on mandate wins or expansion in observable ITC activity over the next 6–18 months.